Recent Progress in Treatments of Rheumatoid Arthritis: an Overview of Developments in Biologics and Small Molecules, and Remaining Unmet Needs

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2021 Dec 24

PMID 34951925

Citations 23

Authors

Yoshiya Tanaka

Affiliations

Soon will be listed here.

Abstract

Through treatment with biological DMARDs (bDMARDs) or targeted synthetic (tsDMARDs) such as Janus kinase (JAK) inhibitors in addition to MTX, clinical remission has become a realistic therapeutic goal for the majority of patients with RA, and sustained remission facilitates prevention of joint damage and physical dysfunction. Long-term safety and sustained inhibition of structural changes and physical dysfunction by bDMARDs have been reported. The development of next-generation bDMARDs and expansion of their indications to various autoimmune diseases are expected. Five JAK inhibitors show comparable efficacy to bDMARDs, and the latest ones are effective for overcoming difficult-to-treat RA regardless of prior medications. Patients treated with JAK inhibitors should be adequately screened and monitored for infection, cardiovascular disorders, thrombosis, malignancies and so on. Advances in therapeutic strategies, including the differential use of therapeutic drugs and de-escalation of treatment after remission induction, are prioritized.

Citing Articles

Impact of Disease-Modifying Antirheumatic Drugs on Cognitive Function in Older Adults with Rheumatoid Arthritis.

Fazel S, Carollo M, Tap L, Spini A, Trifiro G, Mattace-Raso F Drugs Aging. 2025; .

PMID: 40088377 DOI: 10.1007/s40266-025-01190-9.

Biomaterials for Modulating the Immune Microenvironment in Rheumatoid Arthritis.

Wang Q, Ji J, Huang D, Gao C BME Front. 2025; 6:0102.

PMID: 40065832 PMC: 11893043. DOI: 10.34133/bmef.0102.

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry.

Kanda R, Miyazaki Y, Nakayamada S, Fukuyo S, Kubo S, Miyagawa I Rheumatol Ther. 2025; .

PMID: 40025347 DOI: 10.1007/s40744-025-00747-9.

First Metatarsophalangeal Joint-Preserving Surgery Is Effective for Forefoot Deformity With Moderate to Severe Joint Destruction in Rheumatoid Arthritis.

Sakai S, Fujiwara T, Yamaguchi R, Yokoyama N, Hara D, Akasaki Y Foot Ankle Orthop. 2025; 10(1):24730114251322790.

PMID: 40013106 PMC: 11863219. DOI: 10.1177/24730114251322790.

Exploring the Role of Macrophages and Their Associated Structures in Rheumatoid Arthritis.

Tian X, Chen J, Hong Y, Cao Y, Xiao J, Zhu Y J Innate Immun. 2025; 17(1):95-111.

PMID: 39938504 PMC: 11820663. DOI: 10.1159/000543444.

References

Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H . Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010; 69(7):1286-91. PMC: 3015067. DOI: 10.1136/ard.2009.121491. View

Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y . Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2018; 58(2):336-344. DOI: 10.1093/rheumatology/key069. View

Rubbert-Roth A, Enejosa J, Pangan A, Haraoui B, Rischmueller M, Khan N . Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020; 383(16):1511-1521. DOI: 10.1056/NEJMoa2008250. View

Genovese M, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y . Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018; 391(10139):2513-2524. DOI: 10.1016/S0140-6736(18)31116-4. View

Cohen S, Tanaka Y, Mariette X, Curtis J, Lee E, Nash P . Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020; 6(3). PMC: 7722371. DOI: 10.1136/rmdopen-2020-001395. View

Harris P, Berger S, Jeong J, Nagilla R, Bandyopadhyay D, Campobasso N . Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. J Med Chem. 2017; 60(4):1247-1261. DOI: 10.1021/acs.jmedchem.6b01751. View

Tanaka Y . Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. J Clin Med. 2021; 10(6). PMC: 8002542. DOI: 10.3390/jcm10061241. View

Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Iwata S, Hanami K . Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. Arthritis Res Ther. 2021; 23(1):154. PMC: 8167961. DOI: 10.1186/s13075-021-02547-2. View

Smolen J, Pangan A, Emery P, Rigby W, Tanaka Y, Ignacio Vargas J . Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019; 393(10188):2303-2311. DOI: 10.1016/S0140-6736(19)30419-2. View

10.

Cohen S, van Vollenhoven R, Winthrop K, Zerbini C, Tanaka Y, Bessette L . Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020; 80(3):304-311. PMC: 7892382. DOI: 10.1136/annrheumdis-2020-218510. View

11.

Narisawa M, Kubo S, Okada Y, Yamagata K, Nakayamada S, Sakata K . Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. Bone. 2020; 142:115616. DOI: 10.1016/j.bone.2020.115616. View

12.

Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Inoue Y, Fujino Y . Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Ann Rheum Dis. 2021; 80(9):1130-1136. PMC: 8372380. DOI: 10.1136/annrheumdis-2020-219699. View

13.

Nagy G, Roodenrijs N, Welsing P, Kedves M, Hamar A, van der Goes M . EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2020; 80(1):31-35. PMC: 7788062. DOI: 10.1136/annrheumdis-2020-217344. View

14.

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

15.

Weinblatt M, McInnes I, Kremer J, Miranda P, Vencovsky J, Guo X . A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis Rheumatol. 2017; 70(1):49-59. PMC: 5767745. DOI: 10.1002/art.40323. View

16.

Genovese M, Weinblatt M, Mease P, Aelion J, Peloso P, Chen K . Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford). 2018; 57(11):1972-1981. DOI: 10.1093/rheumatology/key173. View

17.

. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View

18.

Emery P, Durez P, Hueber A, de la Torre I, Larsson E, Holzkamper T . Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review. Arthritis Res Ther. 2021; 23(1):3. PMC: 7784289. DOI: 10.1186/s13075-020-02379-6. View

19.

Kerschbaumer A, Sepriano A, Smolen J, van der Heijde D, Dougados M, van Vollenhoven R . Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020; 79(6):744-759. PMC: 7286044. DOI: 10.1136/annrheumdis-2019-216656. View

20.

Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M . The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015; 17:135. PMC: 4476083. DOI: 10.1186/s13075-015-0651-0. View